Cornercap Investment Counsel Inc. Has $175,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)

Cornercap Investment Counsel Inc. decreased its position in Cogent Biosciences, Inc. (NASDAQ:COGT) by 52.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 16,165 shares of the technology company’s stock after selling 17,973 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Cogent Biosciences were worth $175,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in Cogent Biosciences by 124.5% in the second quarter. Point72 Asset Management L.P. now owns 14,986,398 shares of the technology company’s stock valued at $126,335,000 after acquiring an additional 8,310,150 shares during the period. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Cogent Biosciences in the 2nd quarter valued at approximately $1,077,000. Sofinnova Investments Inc. lifted its position in shares of Cogent Biosciences by 15.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,773,286 shares of the technology company’s stock worth $23,379,000 after buying an additional 372,515 shares during the period. Janus Henderson Group PLC boosted its stake in Cogent Biosciences by 12,785.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,099,357 shares of the technology company’s stock valued at $14,097,000 after buying an additional 2,083,065 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C grew its stake in Cogent Biosciences by 144.0% during the second quarter. Deerfield Management Company L.P. Series C now owns 3,744,263 shares of the technology company’s stock worth $31,564,000 after buying an additional 2,209,918 shares during the last quarter.

Cogent Biosciences Stock Up 1.0 %

Cogent Biosciences stock opened at $8.99 on Tuesday. The business’s 50-day simple moving average is $10.95 and its 200 day simple moving average is $9.60. The stock has a market cap of $993.04 million, a price-to-earnings ratio of -3.62 and a beta of 1.72. Cogent Biosciences, Inc. has a 12-month low of $3.67 and a 12-month high of $12.61.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, November 12th. The technology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same quarter last year, the business posted ($0.64) EPS. As a group, sell-side analysts expect that Cogent Biosciences, Inc. will post -2.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on COGT. Needham & Company LLC decreased their price target on Cogent Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. JPMorgan Chase & Co. raised their target price on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Cogent Biosciences in a report on Monday, November 4th. Wedbush reissued a “neutral” rating and set a $11.00 price objective on shares of Cogent Biosciences in a report on Tuesday, November 12th. Finally, Citigroup raised their price objective on shares of Cogent Biosciences from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Cogent Biosciences has a consensus rating of “Moderate Buy” and an average target price of $14.83.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.